TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19254119
Drug: Metronidazole 500
Normalized name: metronidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 500 mg and Amoxicillin 375 mg, three times a day for 7 days
Study: 20059413
Drug: Metronidazole and
Normalized name: metronidazole and diloxanide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole and Amoxicillin
Study: 18065809
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg daily for 4 weeks)
Study: 10225812
Drug: Parenteral gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral gold salt therapy
Study: 10225812
Drug: Parenteral gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral gold salt therapy (withdrawn due to side effects)
Study: 8876346
Drug: Ginseng (GS)
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng (GS) 8 or 16 mg/kg body weight daily for 7 days
Study: 31682026
Drug: 1-L PEG
Normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-L PEG
Study: 29498469
Drug: vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: vildagliptin (50 mg twice daily)
Study: 29498469
Drug: dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: dapagliflozin (10 mg once daily)
Study: 24021029
Drug: SumaRT/Nap (85
Approvals — FDA: no, EMA: no, PMDA: no
Description: SumaRT/Nap (85 mg sumatriptan + 500 mg naproxen sodium)
Study: 24020994
Drug: naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen sodium (500 mg)
Study: 22503574
Drug: 18 mg
Normalized name: niacin 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg nicotine e‐cigarette
Study: 22503574
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg e‐cigarette (placebo)
Study: 15988695
Drug: Hydrocortisone (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (12.5 mg/h IV)
Study: 9608969
Drug: Scheduled administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled administration of acetaminophen (60 mg.kg-1.24h-1 orally, 90 mg.kg-1.24h-1 rectally)
Study: 9608969
Drug: Acetaminophen 'as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 'as needed' (control group)
Study: 7658599
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg recombinant human GH for 7 to 13 days
Study: 28475943
Drug: Motivational Interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Interviewing Treatment Integrity coding system 4.2 (MITI 4.2)
Study: 21982529
Drug: Fluconazole 200
Normalized name: fluconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 200 mg three times per week
Study: 16522388
Drug: Antibiotic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic group (oral azithromycin 1 g twice, plus metronidazole 750 mg daily for 7 days)
Study: 8699051
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of sorivudine
Study: 1526858
Drug: Daily treatment
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 g TOPICAL GEL [Acne defense Daily Treatment Serum Merle Norman]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily treatment regimen delivering 2 Gy per fraction
Study: 1526858
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly treatment regimen delivering 5.4 Gy per fraction
Study: 29794092
Drug: Gelatine tannate
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatine tannate (250-500 mg, four times per day for 5 days)
Study: 24813026
Drug: Duloxetine (60‐120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60‐120 mg once daily, n=117)
Study: 24813026
Drug: Fluoxetine (20‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20‐40 mg once daily, n=117)
Study: 20033907
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (risperidone, olanzapine, aripiprazole)
Study: 8567844
Drug: Combined leuprolide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined leuprolide (3.75 mg every 27 days) plus conventional therapy (group A)
Study: 8567844
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy alone (group B)
Study: 8567844
Drug: GnRHa treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa treatment (group C)
Study: 2358736
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (CT) by injection sclerotherapy or rubber band ligation
Study: 26383695
Drug: Interactive Behavioural
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive Behavioural Modification Therapy (IBMT)
Study: 19284932
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (Nortriptyline and Sertraline)
Study: 8197035
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg plus paracetamol 325 mg
Study: 8197035
Drug: Dextropropoxyphene 65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextropropoxyphene 65 mg plus paracetamol 400 mg
Study: 3592300
Drug: Propranolol (0.01,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.01, 0.02, 0.03, and 0.04 mg/kg IV)
Study: 3592300
Drug: Pindolol (0.001,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (0.001, 0.002, 0.003, and 0.004 mg/kg IV)
Study: 31358477
Drug: Testosterone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (200 mg testosterone enanthate per week)
Study: 25223181
Drug: Qingfei Peiyuan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingfei Peiyuan Micro‐pill (QPM)
Study: 25223181
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Western medicine only)
Study: 15322960
Drug: Once-daily extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily extended-release methylphenidate
Study: 15322960
Drug: Twice-daily immediate-release
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily immediate-release methylphenidate
Study: 2994320
Drug: Preoperative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative therapy (chemotherapy or radiotherapy)
Study: 3280589
Drug: Domperidone (DMP)
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (DMP) administration
Study: 31433919
Drug: Serelaxin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serelaxin (30 μg per kilogram of body weight per day) for 48 hours
Study: 27786603
Drug: Clopidogrel (18.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (18.75 mg/cat q24h for seven days)
Study: 25394856
Drug: Glycine air‐powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine air‐powder system (SGA) adjuncted to professional oral hygiene (POH)
Study: 25394856
Drug: Professional oral
Normalized name: Dentek Professional Oral Care Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional oral hygiene (POH)
Study: 22581270
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (n = 111)
Study: 21736844
Drug: Lupin beverage
Normalized name: Lupinus albus seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupin beverage (50 g glucose + 12.5 g fibre + 22 g protein)
Study: 21736844
Drug: Soya beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soya beverage (50 g glucose + 12.5 g fibre + 22 g protein)
Study: 20101858
Drug: High-dose misoprostol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose misoprostol (maximum total dose 1400 g)
Study: 20101858
Drug: Low-dose misoprostol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose misoprostol (maximum total dose 1400 g)
Study: 3079695
Drug: High-dose misoprostol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose misoprostol
Study: 3079695
Drug: Low-dose misoprostol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose misoprostol
Study: 20166794
Drug: Aripiprazole 30
Normalized name: aripiprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 30 mg/day
Study: 15551047
Drug: Losartan, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan, 100 mg once daily
Study: 8393058
Drug: Foscarnet 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet 90 mg/kg/day infusion administered over 2 h
Study: 8393058
Drug: Foscarnet 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet 120 mg/kg/day infusion administered over 2 h
Study: 2883129
Drug: Terfenadine (H1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (H1 histamine receptor antagonist)
Study: 29870736
Drug: pyrimethamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyrimethamine (50 mg qd) + sulfadiazine (1 g tid) with folinic acid
Study: 29870736
Drug: spiramycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: spiramycin (1 g tid)
Study: 19553184
Drug: Ciprofloxacin tablets
Normalized name: Ciprofloxacin Tablets
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin tablets
Study: 15911730
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of simvastatin plus 15 g of psyllium (Metamucil) daily
Study: 15911730
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of simvastatin plus placebo
Study: 15911730
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of simvastatin plus placebo
Study: 8602988
Drug: rhEPO (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO (2 x 300 U/kg) and parenteral iron (2 x 200mg) with a 72 h interval
Study: 8602988
Drug: rhEPO (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO (2 x 300 U/kg) and parenteral iron (2 x 200mg) with a 24 h interval
Study: 8602988
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received parenteral iron only
Study: 24625805
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of inactivated EV71 vaccine (160 U, 320 U, and 640 U with adjuvant and 640 U without adjuvant)
Study: 12058997
Drug: Polymyxin B
Normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polymyxin B immobilized fiber (PMX‐F) treatment
Study: 12058997
Drug: Septic trauma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Septic trauma patients before treatment
Study: 12058997
Drug: Septic trauma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Septic trauma patients after treatment
Study: 3545718
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g qid)
Study: 7697902
Drug: Mucosal-coating compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucosal-coating compounds
Study: 7697902
Drug: Gastric antisecretory
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric antisecretory drugs
Study: 241932
Drug: Betaket (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaket (combination of beta-receptor blocker and isosorbide dinitrate)
Study: 241932
Drug: Betadrenol (beta-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betadrenol (beta-receptor blocker)
Study: 241932
Drug: Isoket (isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoket (isosorbide dinitrate preparation)
Study: 22921680
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy (n=72), administered 24 hours after rt-PA for 10 days
Study: 22921680
Drug: Non-antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-antiplatelet therapy (n=74), received no antiplatelet therapy
Study: 15920051
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin spray (20 puffs)
Study: 15920051
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin spray (5, 10, and 20 puffs)
Study: 15920051
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin spray
Study: 15983312
Drug: Subcutaneous regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous regular insulin
Study: 9700963
Drug: 0 drops
Normalized name: MENTHOL 2.7 mg ORAL SUSPENSION/ DROPS [FREEGELLS COUGH DROPS MENTHOL STRAWBERRY 30 DROPS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 drops of corn syrup solution
Study: 9700963
Drug: 1 drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of corn syrup solution
Study: 9700963
Drug: 2 drops
Normalized name: CHOLECALCIFEROL 12.5 ug in 0.04 mL / MENAQUINONE 7 50 ug in 0.04 mL ORAL SOLUTION/ DROPS [YYUX Organic Liquid Vitamin D3 plus K2 Drops]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 drops of corn syrup solution
Study: 9700963
Drug: 3 drops
Normalized name: UpSpring WellBaby DHA + Vitamin D3 Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 drops of corn syrup solution
Study: 6892479
Drug: Lysine‐8‐vasopressin (LVP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine‐8‐vasopressin (LVP) 5 I.U. administered intranasally daily for 5 days
Study: 6892479
Drug: NaCl administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl administered intranasally daily for 5 days (control group)
Study: 22384088
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus injection of erythropoietin, acute effects studied for 1-10 hours.
Study: 22384088
Drug: Prolonged administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged administration of recombinant human erythropoietin (rHuEpo) for 16 days.
Study: 20829661
Drug: Wound cleansing
Normalized name: Restore Wound Cleansing Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound cleansing solution containing polihexanide and betaine
Study: 11489001
Drug: Epirubicin in
Normalized name: epirubicin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin in combination with carboplatin and paclitaxel (ET-Carbo)
Study: 7595261
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole 500 mg twice daily for 1 week
Study: 7595261
Drug: Metronidazole vaginal
Normalized name: MetroNIDAZOLE Vaginal
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole vaginal gel 0.75% 5 g twice daily for 5 days
Study: 7595261
Drug: Clindamycin vaginal
Normalized name: clindamycin Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin vaginal cream 2% 5 g once daily for 7 days
Study: 2292207
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g as a single preoperative dose
Study: 2292207
Drug: Cefotaxime 1
Normalized name: cefotaxime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 1 g preoperative dose plus 9 postoperative doses every 8 h for 3 days
Study: 7407745
Drug: L-tryptophan (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (6 grams daily)
Study: 7407745
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 grams daily)
Study: 31551225
Drug: Mucopolysaccharide polysulfate
Normalized name: Mucopolysaccharide polysulfate
DrugBank: Mucopolysaccharide polysulphate (DB16564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucopolysaccharide polysulfate ointment combined with desonide ointment
Study: 31551225
Drug: Desonide ointment
Normalized name: Desonide Ointment
DrugBank: Desonide sodium phosphate (DB15835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desonide ointment only
Study: 29046015
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (30 mg/kg bolus dose and infusion at 10 mg/kg/h)
Study: 24631042
Drug: A manihot
Normalized name: Abelmoschus manihot whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: A manihot (huangkui capsule), 2.5 g, 3 times per day
Study: 24631042
Drug: Losartan potassium,
Normalized name: Losartan Potassium, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan potassium, 50 mg/d
Study: 24631042
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (A manihot + losartan)
Study: 23115404
Drug: Nightly zolpidem,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nightly zolpidem, 10 mg (5 mg for patients > 60 yrs)
Study: 19569018
Drug: Oral phosphate
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral phosphate (Pi) load (100 mmol) in NTS group
Study: 19569018
Drug: Oral phosphate
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral phosphate (Pi) load (100 mmol) in CNT group
Study: 19569018
Drug: Oral phosphate
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral phosphate (Pi) load (100 mmol) in NTS and CNT groups
Study: 11473947
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (ganirelix) during ovarian stimulation for IVF or ICSI
Study: 8065723
Drug: 0.05% clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasol propionate ointment in orabase
Study: 8065723
Drug: 0.05% fluocinonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% fluocinonide ointment in orabase
Study: 8065723
Drug: Both medications
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both medications (clobetasol propionate and fluocinonide)
Study: 2115186
Drug: PGI2 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGI2 (6 ng/kg/min over 8 hours daily for 5 consecutive days)
Study: 28917370
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no inhalation)
Study: 25929192
Drug: ALN/D5600 (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN/D5600 (70 mg/vitamin D3 5600 IU) once weekly
Study: 25929192
Drug: Calcitriol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.25 μg/day)
Study: 20692843
Drug: Arthrocentesis combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrocentesis combined with splint therapy
Study: 20692843
Drug: Rest therapy
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rest therapy (restricting mouth opening, analgesic therapy)
Study: 17764004
Drug: Splint therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Splint therapy
Study: 11417777
Drug: Nicotine sublingual
Normalized name: nicotine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine sublingual tablet
Study: 15571272
Drug: Allopurinol (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (standard treatment)
Study: 9783530
Drug: Trifazid (fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifazid (fixed-dose combination of rifampicin, isoniazid, and pyrazinamide)
Study: 3180489
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 6.25 mg
Study: 8583780
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 25 mg
Study: 6387965
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 50 mg
Study: 5309530
Drug: ID-Jet 1
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID-Jet 1 vaccine (10(7.0) TCID(50)/ml)
Study: 5309530
Drug: ID-Jet 1a
Normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ID-Jet 1a vaccine (10(6.3) TCID(50)/ml)
Study: 5309530
Drug: ID-Jet 2
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID-Jet 2 vaccine (10(6.0) TCID(50)/ml)
Study: 29717351
Drug: Colon Capsule
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colon Capsule Endoscopy (CCE)
Study: 31154945
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (ESCAPE trial)
Study: 31154945
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (Quality Improvement and Clinical Research patients)
Study: 25433572
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine 0.125% with fentanyl 2 μg/mL at 37°C
Study: 25433572
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine 0.125% with fentanyl 2 μg/mL at 20°C
Study: 23228072
Drug: Transcription error
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcription error rates for inpatient medications
Study: 23228072
Drug: Transcription error
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcription error rates for discharge patient medications
Study: 18771605
Drug: Thiopental (subanaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (subanaesthetic doses)
Study: 16673208
Drug: Morning insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning insulin glargine plus morning glimepiride (2, 3 or 4 mg)
Study: 16673208
Drug: Bedtime insulin
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime insulin glargine plus morning glimepiride (2, 3 or 4 mg)